Efficacy of continuous glucose monitoring system (CGMS) to detect postprandial hyperglycemia and unrecognized hypoglycemia in type 1 diabetic patients

Maia, Frederico Fernandes Ribeiro; Araújo, Levimar R.

doi:10.1016/j.diabres.2006.05.009

Cited by 70 publications

(35 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…5 Continuous glucose monitoring (CGM) systems are able to provide a glucose value every three to five minutes. Compared to self-monitoring of blood glucose (SMBG), CGM can detect more periods of hypoglycemia 6 and more frequent nocturnal hypoglycemia. 7 Their use in adults improves glycemic control.…”

Section: Introductionmentioning

confidence: 99%

Patients' Perception and Future Acceptance of an Artificial Pancreas

Bon

Kohinor

Hoekstra

et al. 2010

J Diabetes Sci Technol

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

Patients' Perception and Future Acceptance of an Artificial Pancreas

Bon

Kohinor

Hoekstra

et al. 2010

J Diabetes Sci Technol

View full text Add to dashboard Cite

“…This device also represents a useful tool for researchers to obtain robust, quantitative data from human subjects. 8,9 However, few studies to date have used the CGM system to evaluate the effects of oral antidiabetes drugs on glucose variability. Nateglinide and acarbose are two of the oral antidiabetes drugs that preferentially affect postprandial hyperglycemia and are widely used to treat T2DM patients in China.…”

mentioning

confidence: 99%

Nateglinide and Acarbose Are Comparably Effective Reducers of Postprandial Glycemic Excursions in Chinese Antihyperglycemic Agent–Naive Subjects with Type 2 Diabetes

Zhou

Zhang

et al. 2013

Diabetes Technology & Therapeutics

View full text Add to dashboard Cite

Background: Recent studies have identified postprandial glycemic excursions as risk factors for diabetes complications. This study aimed to compare the effects of nateglinide and acarbose treatments on postprandial glycemic excursions in Chinese subjects with type 2 diabetes. Subjects and Methods: This was a multicenter, open-label, randomized, active-controlled, parallel-group study. One hundred three antihyperglycemic agent-naive subjects with type 2 diabetes (hemoglobin A1c range, 6.5-9.0%) were prospectively recruited from four hospitals in China. The intervention was nateglinide (120 mg three times a day) or acarbose (50 mg three times a day) therapy for 2 weeks. A continuous glucose monitoring system was used to calculate the incremental area under the curve of postprandial blood glucose (AUC pp ), the incremental glucose peak (IGP), mean amplitude of glycemic excursions, SD of blood glucose, the mean of daily differences, and 24-h mean blood glucose (MBG). Subjects' serum glycated albumin and the plasma insulin levels were also analyzed. Results: Both agents caused significant reductions on AUC pp and IGP. Similarly, both treatment groups showed significant improvements in the intra-and interday glycemic excursions, as well as the 24-h MBG and serum glycated albumin compared with baseline (P < 0.001). However, neither of the agents produced a significantly better effect (P > 0.05). Moreover, the nateglinide-treated group had significantly increased insulin levels at 30 min and at 120 min after a standard meal compared with baseline, whereas the acarbose-treated group decreased. No serious adverse events occurred in either group. The rates of hypoglycemic episodes were comparable in the two groups, and no severe hypoglycemic episode occurred in either group. Conclusions: Nateglinide and acarbose were comparably effective in reducing postprandial glycemic excursions in antihyperglycemic agent-naive Chinese patients with type 2 diabetes, possibly through different pathophysiological mechanisms.

show abstract

“…In total, 10 [56][57][58]66,[74][75][76][77][78][79] of the 15 CGMS studies that reported on adverse events found no evidence of either skin irritation or inflammation and no adverse device-related events. Of the remaining five studies, one 41 reported seven device-related adverse events, all involving minor irritation of the sensor insertion site, and another 64 reported five adverse device-related events.…”

Section: Cgms Studiesmentioning

confidence: 99%

“…the length of time and number of times that the monitor was worn. Five 57,74,75,77,79 of the ten studies that reported no adverse devicerelated events, skin irritation or inflammation required the CGMS to be worn once. Amongst the other five studies the CGMS was worn once or more, 41 twice, 56 three times 58 or four times.…”

Section: Doi: 103310/hta13280mentioning

confidence: 99%

See 1 more Smart Citation

A randomised controlled trial to compare minimally invasive glucose monitoring devices with conventional monitoring in the management of insulin-treated diabetes mellitus (MITRE)

Newman

Cooke²,

Casbard³

et al. 2009

Health Technol Assess

View full text Add to dashboard Cite

How to obtain copies of this and other HTA programme reports An electronic version of this publication, in Adobe Acrobat format, is available for downloading free of charge for personal use from the HTA website (www.hta.ac.uk). A fully searchable CD-ROM is also available (see below).Printed copies of HTA monographs cost £20 each (post and packing free in the UK) to both public and private sector purchasers from our Despatch Agents.Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per monograph and for the rest of the world £3 per monograph.You can order HTA monographs from our Despatch Agents:-fax (with credit card or official purchase order) -post (with credit card or official purchase order or cheque) -phone during office hours (credit card only).Additionally the HTA website allows you either to pay securely by credit card or to print out your order and then post or fax it. Contact details are as follows: Payment methods Paying by chequeIf you pay by cheque, the cheque must be in pounds sterling, made payable to Direct Mail Works Ltd and drawn on a bank with a UK address. Paying by credit cardThe following cards are accepted by phone, fax, post or via the website ordering pages: Delta, Eurocard, Mastercard, Solo, Switch and Visa. We advise against sending credit card details in a plain email. Paying by official purchase orderYou can post or fax these, but they must be from public bodies (i.e. NHS or universities) within the UK. We cannot at present accept purchase orders from commercial companies or from outside the UK. How do I get a copy of HTA on CD?Please use the form on the HTA website (www.hta.ac.uk/htacd.htm). Or contact Direct Mail Works (see contact details above) by email, post, fax or phone. HTA on CD is currently free of charge worldwide.The website also provides information about the HTA programme and lists the membership of the various committees. HTA NIHR Health Technology Assessment programmeT he Health Technology Assessment (HTA) programme, part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research information on the effectiveness, costs and broader impact of health technologies for those who use, manage and provide care in the NHS. 'Health technologies' are broadly defined as all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care. The research findings from the HTA programme directly influence decision-making bodies such as the National Institute for Health and Clinical Excellence (NICE) and the National Screening Committee (NSC). HTA findings also help to improve the quality of clinical practice in the NHS indirectly in that they form a key component of the 'National Knowledge Service'. The HTA programme is needs led in that it fills gaps in the evidence needed by the NHS. There are three routes to the start of projects. First is the commissioned route. Suggestions for research are actively sought from people working in t...

show abstract

Efficacy of continuous glucose monitoring system (CGMS) to detect postprandial hyperglycemia and unrecognized hypoglycemia in type 1 diabetic patients

Cited by 70 publications

References 30 publications

Patients' Perception and Future Acceptance of an Artificial Pancreas

Patients' Perception and Future Acceptance of an Artificial Pancreas

Nateglinide and Acarbose Are Comparably Effective Reducers of Postprandial Glycemic Excursions in Chinese Antihyperglycemic Agent–Naive Subjects with Type 2 Diabetes

A randomised controlled trial to compare minimally invasive glucose monitoring devices with conventional monitoring in the management of insulin-treated diabetes mellitus (MITRE)

Contact Info

Product

Resources

About